Ibsa Institut Biochimique Sa Patent-Cliff Exposure & CMS Drug Spending Portfolio

Ibsa Institut Biochimique Sa (US): 5 reconciled FDA prescription therapies, $39.4M 2024 CMS Part D & Medicaid spend, and 1 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies5
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2033-01-01
2024 CMS Total Public Spend$39.4M
2024 Medicare Part D Spend$28.8M
2024 Medicaid Spend$10.7M
California HCAI SB 17 Filings1 WAC filings (max 24.2% 2-yr change)